Skip to content

INVESTORS & MEDIA

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Oct 25, 2012
THOUSAND OAKS, Calif. and MENLO PARK, Calif. (Oct. 25, 2012) – Amgen and Kleiner Perkins Caufield & Byers (KPCB) today announced the formation of Atara Biotherapeutics, (www.atarabio.com), a new drug development company with a focus on innovative therapies for patients with chronic dise...
Aug 28, 2013
A team of oncology researchers including Dr. Christopher Haqq, Atara Biotherapeutics’ Chief Medical Officer, presented a poster at the June 2013 annual meeting of the American Society of Clinical Oncology in Chicago. The findings were published in the Journal of Clinical Oncology: “Effects of a soluble activin type 2B receptor Fc fusion...
Dec 17, 2013
BRISBANE, Calif. and THOUSAND OAKS, Calif., December 17, 2013 – Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors ...
Jan 10, 2014
BRISBANE, Calif. and THOUSAND OAKS, Calif., January 10, 2013 – Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today a second closing of its recently announced Series B financing, bringing the total rais...
Apr 8, 2014
BRISBANE and THOUSAND OAKS, Calif., April 8, 2014 – Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has strengthened its board of directors and executive team by appointing Matthew K. Fust as a director and hiring Mitchall G. C...
Sep 23, 2014
Brisbane, CA – [September 23, 2014] – Atara Biotherapeutics (Atara) today announced that they have entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Under...
Oct 15, 2014
BRISBANE, Calif., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $11.00 per share, bef...
Oct 22, 2014
BRISBANE, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin inhibitor, in patients with ovarian cancer and other ...
Nov 6, 2014
BRISBANE, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present at the Annual Meeting of...
Nov 12, 2014
BRISBANE, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today reported financial results for the third quarter and nine months ended September 30, 2014. "Atara has made significant accompli...
Jan 9, 2015
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 J.P. Morgan Healt...
Feb 9, 2015
SOUTH SAN FRANCISCO, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. In addition, Ata...
Feb 12, 2015
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its underwritten public offering of 3,638,333 shares of its common stock at a public offering p...
Feb 18, 2015
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the closing of its public offering of 4,147,358 shares of its common stock at a public offering price of $18.0...
Feb 26, 2015
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the fourth quarter and full year ended December 31, 2014. "2014 was a significant year...
Page:
...
Next Last
 
= add release to Briefcase